Vortioxetine as adjunctive therapy in the treatment of schizophrenia
Journal article
Redaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, O., Lewis, Gabriella, Lobo, Maria, Whiskey, E. and Shergill, Sukhi S. 2022. Vortioxetine as adjunctive therapy in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology. 12, p. 204512532211100. https://doi.org/10.1177/20451253221110014
| Authors | Redaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, O., Lewis, Gabriella, Lobo, Maria, Whiskey, E. and Shergill, Sukhi S. |
|---|---|
| Abstract | Background: The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking. Objectives: Vortioxetine is a novel antidepressant that has been used as adjunctive therapy for the treatment of psychosis; however, its effectiveness in clinical practice is relatively unknown. In this study, we aimed to determine the potential clinical effectiveness and safety and tolerability of vortioxetine in psychosis. Design: This is a non-interventional, retrospective study on the add-on use of vortioxetine in a group of people with schizophrenia-spectrum disorders in a large UK NHS mental health trust. Methods: Clinical effectiveness of vortioxetine was retrospectively assessed through the Clinical Global Impression – Severity (CGI-S) scale at 3 months. Safety and tolerability were evaluated through treatment discontinuation rates at 3, 6, and 12 months, and clinical reasons were evaluated at the primary endpoint of 3 months. Results: Data were available for 40 subjects with a diagnosis of schizophrenia or schizoaffective disorder–prescribed vortioxetine treatment; 30 (75%) remained on treatment at 3 months. At CGI-S assessment, 15 of the 35 evaluated subjects reported at least a 1-point improvement, from 5 at baseline to 4 after 3 months of treatment. Twenty-six (65%) remained on treatment at 1-year follow-up. The main reasons for those discontinuing treatment were inadequate response (10%) and manic switch (7.5%), while one subject refused treatment. Tolerability to treatment was good, and 36 subjects (90%) reported no adverse events specific to vortioxetine treatment. Conclusion: Schizophrenia is a complex illness, and there is insufficient treatment response in many individuals. A significant proportion of whom may require adjunctive treatments depending on the nature of the residual symptoms. Vortioxetine could be a potentially safe and effective option in such people, but further controlled studies are required. |
| Keywords | Vortioxetine ; Schizophrenia; Treatment |
| Year | 2022 |
| Journal | Therapeutic Advances in Psychopharmacology |
| Journal citation | 12, p. 204512532211100 |
| Publisher | SAGE Publications |
| ISSN | 2045-1253 |
| 2045-1261 | |
| Digital Object Identifier (DOI) | https://doi.org/10.1177/20451253221110014 |
| Official URL | https://journals.sagepub.com/doi/full/10.1177/20451253221110014 |
| Funder | King's College London |
| Publication dates | |
| Online | 05 Jul 2022 |
| Publication process dates | |
| Accepted | 08 Jun 2022 |
| Deposited | 18 Jul 2022 |
| Publisher's version | License |
| Output status | Published |
Permalink -
https://repository.canterbury.ac.uk/item/9180q/vortioxetine-as-adjunctive-therapy-in-the-treatment-of-schizophrenia
Download files
127
total views37
total downloads2
views this month0
downloads this month